If you're sitting in an R&D or NPD seat right now, you already feel it. Fiber stopped being the thing you added so the back of the bar said 4g fiber in small print. Now it's the thing that makes the product work in the GLP-1 era. The category turned.
What's pulling the wave:
- The GLP-1 era. Consumers on Ozempic, Wegovy, Mounjaro, and Zepbound are actively searching for satiety, regularity, blood-sugar stability, and gentle digestion. Fiber sits at the center of every one of those needs.
- The gut-health boom. Probiotics fed the trend. Prebiotic fiber is now feeding the gains.
- Blood-sugar awareness. CGMs are in the hands of biohackers, keto consumers, and increasingly your everyday shopper. They are watching the spike. Soluble fiber blunts it.
- The protein backlash. The category defining snacking for a decade is being repositioned — and fiber is the repositioning lever.
- FDA tightening on what counts as fiber. What lands on the Nutrition Facts panel matters more every year. And that brings us to the next problem.
The IMO Problem
If your fiber story is built on IMO (isomaltooligosaccharides), you are already living the headline.
- The FDA denied IMO's petition to be classified as dietary fiber (Jan 2020) — citing insufficient evidence of a qualifying physiological benefit.
- FDA's own GRAS review of IMO documented studies showing it is nearly completely digested to glucose in the GI tract.
- Brands that built fiber claims on IMO are rebuilding them. Right now. On a deadline.
Fiberyum is not an IMO. It's a tapioca-based resistant dextrin sitting inside FDA's dietary fiber guidance framework. A category, a regulatory posture, and a label story that's defensible today and stays defensible tomorrow. Cleaner regulatory story. Stronger fiber claim. One less thing keeping your regulatory team up at night.